Activity of combination abacavir/amprenavir/efavirenz therapy in HIV-1 infected subjects failing their current protease inhibitor containing regimen

被引：0
|
作者：
Eron, J
Falloon, J
Masur, H
Ait-Khaled, M
Thomas, D
Manion, D
Rogers, M
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] NIAID, NIH, Bethesda, MD 20892 USA
[3] Glaxo Wellcome Inc, Stevenage, Herts, England
[4] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
[5] DuPont Pharmaceut, Wilmington, DE USA
来源：
AIDS | 1998年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OP52
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [21] Primary and secondary mutations in the RT and protease gene in HIV-1 infected patients predict failing to specific antiretroviral combination therapy
    Arasteh, K
    Simon, V
    Sternfeld, T
    Kunz, A
    Zwingers, T
    Kurowski, M
    L'Age, M
    AIDS, 2000, 14 : S118 - S118
  • [22] Clonal analysis of protease and gag sequences from HIV-1 subtype C infected patients failing a protease inhibitor
    Ledwaba, J.
    Pillay, V.
    Morris, L.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A50 - A50
  • [23] Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children
    Stein, DS
    Lou, Y
    Johnson, M
    Randall, S
    Blanche, S
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (11): : 1301 - 1308
  • [24] Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients
    Villani, P
    Regazzi, MB
    Castelli, F
    Viale, P
    Torti, C
    Seminari, E
    Maserati, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (05) : 712 - 715
  • [25] Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects
    Paulsen, D
    Elston, R
    Snowden, W
    Tisdale, M
    Ross, L
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) : 319 - 323
  • [26] Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients
    Khanna, N
    Klimkait, T
    Schiffer, V
    Irigoyen, J
    Telenti, A
    Hirschel, B
    Battegay, M
    AIDS, 2000, 14 (07) : 791 - 799
  • [27] Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study
    Friedl, AC
    Ledergerber, B
    Flepp, M
    Hirschel, B
    Telenti, A
    Furrer, H
    Bucher, HC
    Bernasconi, E
    Weber, R
    AIDS, 2001, 15 (14) : 1793 - 1800
  • [28] Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor - Containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir
    Abgrall, Sophie
    Yeni, Patrick G.
    Bouchaud, Olivier
    Costagliola, Dominique
    CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) : 120 - 127
  • [29] Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
    Burgos, Joaquin
    Crespo, Manuel
    Falco, Vicenc
    Curran, Adria
    Imaz, Arkaitz
    Domingo, Pere
    Podzamczer, Daniel
    Gracia Mateo, Maria
    Van den Eynde, Eva
    Villar, Sara
    Ribera, Esteve
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) : 1453 - 1458
  • [30] Switch to amprenavir/ritonavir demonstrated superior efficacy compared to the continuation of a protease inhibitor in multiple protease inhibitor-experienced HIV-1-infected subjects with virological failure
    Cattelan, AM
    Pulido, F
    Stark, T
    Elston, R
    ANTIVIRAL THERAPY, 2002, 7 (03) : L71 - L72
12345